Doxazosin Mesylate NDC 29300-354

NDC codes

FDA NDC Directory

Product NDC (as listed)29300-354Labeler and product segments. Claims need a package NDC.

Product NDC at billing width29300-0354Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
29300-354-01	29300035401	100 TABLET in 1 BOTTLE (29300-354-01)Marketed from Mar 15, 2024
29300-354-10	29300035410	1000 TABLET in 1 BOTTLE (29300-354-10)Marketed from Mar 15, 2024
29300-354-13	29300035413	30 TABLET in 1 BOTTLE (29300-354-13)Marketed from Mar 15, 2024

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Doxazosin Mesylate
Generic name (nonproprietary): doxazosin mesylate
Active ingredients: Doxazosin mesylate — 8 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Unichem Pharmaceuticals (USA), Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 212329
Marketing start: Jan 10, 2024
Listing expires: Dec 31, 2026
Other FDA classes: Adrenergic alpha-Antagonists (Mechanism)
Identifiers: Product ID 29300-354_e2406e8e-68c2-49dc-9e15-6170f3fffa03SPL ID e2406e8e-68c2-49dc-9e15-6170f3fffa03SPL set ID 44bfe5d7-a56a-46f1-8ef3-ad386ab35f0fRxCUI 197625, 197626, 197627, 197628UNII 86P6PQK0MU
Pharmacologic class: alpha-Adrenergic Blocker

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N429300035401 followed by a unit qualifier and the quantity

Package 29300-0354-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 23, 2024.

Indications (excerpt from the label)

Doxazosin tablets are an alpha 1 adrenergic antagonist indicated for: Signs and symptoms of Benign Prostatic Hyperplasia (BPH) Treatment of Hypertension 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk offatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 212329

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 212329
Product	Strength	Form · route	Labeler	Product NDC
Doxazosin Mesylate	Doxazosin mesylate 2 mg/1	TabletOral	Unichem Laboratories Limited, India	53747-352
Doxazosin Mesylate	Doxazosin mesylate 1 mg/1	TabletOral	Unichem Pharmaceuticals (USA), Inc.	29300-351
Doxazosin Mesylate	Doxazosin mesylate 2 mg/1	TabletOral	Unichem Pharmaceuticals (USA), Inc.	29300-352
Doxazosin Mesylate	Doxazosin mesylate 4 mg/1	TabletOral	Unichem Pharmaceuticals (USA), Inc.	29300-353